Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP). Gandaglia G, et al. Among authors: surcel ci. BJU Int. 2018 Nov;122(5):823-830. doi: 10.1111/bju.14391. Epub 2018 Jun 3. BJU Int. 2018. PMID: 29772103
The oncologic role of local treatment in primary metastatic prostate cancer.
Ghadjar P, Briganti A, De Visschere PJ, Fütterer JJ, Giannarini G, Isbarn H, Ost P, Sooriakumaran P, Surcel CI, van den Bergh RC, van Oort IM, Yossepowitch O, Ploussard G. Ghadjar P, et al. Among authors: surcel ci. World J Urol. 2015 Jun;33(6):755-61. doi: 10.1007/s00345-014-1347-9. Epub 2014 Jul 5. World J Urol. 2015. PMID: 24997127 Review.
Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients.
Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, Surcel CI, Salomon L, Freschi M, Mirvald C, van der Poel HG, Jenkins A, Ost P, van Oort IM, Yossepowitch O, Giannarini G, van den Bergh RC; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Ploussard G, et al. Among authors: surcel ci. Urol Oncol. 2015 Feb;33(2):71.e1-9. doi: 10.1016/j.urolonc.2014.07.007. Epub 2014 Aug 15. Urol Oncol. 2015. PMID: 25131660
What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
Gandaglia G, Ploussard G, Isbarn H, Suardi N, De Visschere PJ, Futterer JJ, Ghadjar P, Massard C, Ost P, Sooriakumaran P, Surcel CI, van der Bergh RC, Montorsi F, Ficarra V, Giannarini G, Briganti A; Prostate Cancer Working Group of Young Academic Urologists Working Party of European Association of Urology. Gandaglia G, et al. Among authors: surcel ci. Urol Oncol. 2015 Apr;33(4):164.e1-9. doi: 10.1016/j.urolonc.2014.12.011. Epub 2015 Jan 22. Urol Oncol. 2015. PMID: 25620154
Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling.
Isbarn H, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Giannarini G, Ost P, Ploussard G, Sooriakumaran P, Surcel CI, van Oort IM, Yossepowitch O, van den Bergh RC; Prostate Cancer Working Group of the European Association of Urology Young Academic Urologists. Isbarn H, et al. Among authors: surcel ci. Arch Esp Urol. 2015 Apr;68(3):296-306. Arch Esp Urol. 2015. PMID: 25948801 Review.
Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.
van den Bergh R, Gandaglia G, Tilki D, Borgmann H, Ost P, Surcel C, Valerio M, Sooriakumaran P, Salomon L, Briganti A, Graefen M, van der Poel H, de la Taille A, Montorsi F, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP). van den Bergh R, et al. Eur Urol Focus. 2019 Mar;5(2):171-178. doi: 10.1016/j.euf.2017.07.003. Epub 2017 Aug 8. Eur Urol Focus. 2019. PMID: 28801241
Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology.
van den Bergh RCN, Ost P, Surcel C, Valerio M, Fütterer JJ, Gandaglia G, Sooriakumaran P, Tilki D, Tsaur I, Ploussard G; European Association of Urology Working Party on Prostate Cancer (EAU-YAUWP). van den Bergh RCN, et al. World J Urol. 2018 Sep;36(9):1489-1494. doi: 10.1007/s00345-018-2278-7. Epub 2018 Apr 2. World J Urol. 2018. PMID: 29610962
Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey.
Marra G, Ploussard G, Ost P, De Visschere PJL, Briganti A, Gandaglia G, Tilki D, Surcel CI, Tsaur I, Van Den Bergh RCN, Kretschmer A, Borgmann H, Gontero P, Ahmed HU, Valerio M; EAU-YAU Prostate Cancer Working Party. Marra G, et al. Among authors: surcel ci. Urol Oncol. 2018 Dec;36(12):529.e11-529.e22. doi: 10.1016/j.urolonc.2018.08.013. Epub 2018 Oct 6. Urol Oncol. 2018. PMID: 30301698
Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Salomon L, Ploussard G, Tilki D; EAU-YAUWP. Preisser F, et al. Among authors: surcel ci. J Urol. 2020 Feb;203(2):338-343. doi: 10.1097/JU.0000000000000504. Epub 2019 Aug 22. J Urol. 2020. PMID: 31437119
31 results